New Study: Double-Blind Trial Confirms Sirtmax® Supports Body Fat Reduction in Overweight Individuals
Published July 29, 2025
12-week placebo-controlled clinical trial highlights the efficacy of Sirtmax® in improving body composition
Purchase, NY | Tuesday, July 29, 2025 — A new randomized, double-blind, placebo-controlled clinical trial published in Frontiers in Nutrition demonstrates that supplementation with Sirtmax®, a patented extract of Kaempferia parviflora, significantly reduces body fat mass, body weight, and BMI in overweight adults over a 12-week period.*
The study enrolled 108 participants, with 83 completing the trial and included in the final analysis. Subjects were randomly assigned to receive either 50mg of Sirtmax® or placebo, with changes assessed from baseline to 12 weeks. Body composition was measured using dual-energy X-ray absorptiometry (DEXA), and computed tomography (CT) imaging was used to evaluate regional fat distribution.
Participants receiving Sirtmax® experienced statistically significant reductions in total body fat mass, subcutaneous fat, and visceral fat compared to placebo.*
Significant Improvements were also observed in body weight, BMI, waist circumference, and the visceral-to-subcutaneous fat ratio.
“Participants maintained their typical diets and activity levels throughout the trial,” researchers noted. “For optimal results, combining Sirtmax® with a higher-protein diet and resistance exercise may help maximize fat loss while preserving lean mass.” These findings suggest that Sirtmax® may serve as a safe and functional ingredient for body fat reduction and obesity management
Reducing visceral fat is a known strategy for improving insulin sensitivity, reducing oxidative stress, and decreasing cardiometabolic risk. The authors suggest that Sirtmax® may offer a novel, natural approach to support body fat metabolism in overweight populations.
Prior clinical studies show that Sirtmax® works by activating the SIRT1 and inhibiting glycation. This results in a favorable impact on adipogenesis and the secretion of adiponectin, protects against oxidative stress, and supports cardiovascular, cellular, and metabolic health.
Maypro, the North American distributor of Sirtmax®, has focused on promoting the ingredient’s unique dual mechanisms of action—both of which provide healthy weight management support. “Sirtmax® demonstrates clinically significant benefits for metabolic health and body composition management in overweight adults,” says Lauren Clardy, Senior Director of Branded Ingredients.
Sirtmax® is the only black ginger on the U.S. market patented for SIRT1 activation. This is largely due to the ingredient’s unique ability to deliver high quantities of KPMF-8 and KPMF-10 which result in significantly higher activation of SIRT1—approximately 5 times greater than resveratrol and 3 times greater than other black gingers that rely on other KPMF for activation,” says Clardy.
Media Inquiries
Danielle Reilly
Director of Marketing Strategy and Public Relations
Maypro Group
[email protected]
(914) 251-0701 x144
About Sirtmax®
Sirtmax® is a patented extract of Kaempferia parviflora standardized for polymethoxyflavones, developed for superior bioactivity and consistent quality. Derived from the rhizome of the black ginger, (Kaempferia parviflora) Sirtmax® is commercialized by Japan based Tokiwa Phytochemical, Co. Ltd. and distributed in North America by Maypro.
About Maypro
Established in 1977, Maypro has become one of the leading global suppliers of proprietary nutraceutical ingredients and ingredient solutions. Maypro has offices located in the United States, Japan, China, and Italy.
About Tokiwa
Tokiwa Phytochemical Co. Ltd. is a company that specializes in phytochemistry. To date, Tokiwa’s ingredients are found in over 2,000 industries. Tokiwa’s 10-acre factory lies in Chiba Prefecture, about one hour from the center of Tokyo. It is where Tokiwa continues to conduct research, develop, and manufacture with passion so that it can always offer the very best botanical products.
